Alphanco Venture Corp Overview
Marvel Biosciences is a Calgary-based, preclinical-stage pharmaceutical developer. It pursues a "drug redevelopment" strategy: it makes patentable synthetic derivatives of drugs that are already approved and off-patent, to target new diseases with less chemistry and safety risk than de novo discovery. Its only clinical-path asset is MB-204, a fluorinated analogue of istradefylline. Istradefylline is the adenosine A2A receptor antagonist approved for Parkinson's disease, and the only approved drug in that class. Marvel positions MB-204 for socio-behavioural symptoms in neurodevelopmental disorders: Rett syndrome, Fragile X syndrome and autism spectrum disorder, with depression as a further indication. Preclinical data show the compound outperforming trofinetide, the only approved Rett therapy, in mouse models. MB-204 has completed cGMP synthesis and 4-week GLP toxicology. The company has composition-of-matter patents granted or allowed in the US, China, Japan and Australia, and it is preparing a first-in-human trial in Australia with Novotech. Marvel has no revenue and a balance sheet with negative equity, so it depends on frequent small equity raises and non-dilutive grants.
Company's own description. In its 2026 press releases, Marvel describes itself and Marvel Biotechnology Inc. as a Calgary-based, preclinical-stage pharmaceutical development company using a drug-redevelopment approach. It also describes itself as a drug-discovery company developing new therapeutics for autism spectrum disorder and related conditions (Newsfile, 20 May 2026 and 29 Sep 2026; Stockwatch, 30 Mar 2026). Its releases explain that A2A blockade has a growing evidence base in neurological diseases beyond Parkinson's, including autism, depression and Alzheimer's disease (Newsfile, 29 Sep 2026).
Business model. Marvel is a single-asset development company. It owns intellectual property and outsources almost all activity:
Discovery and chemistry: designs new chemical entities derived from approved drugs (fluorination of istradefylline in MB-204's case).
Preclinical pharmacology: commissions efficacy studies in animal models of depression, Rett syndrome, Fragile X and autism.
CMC and toxicology: cGMP synthesis and 4-week GLP toxicology are complete (Investing News Network, Novotech release, 2026).
Clinical development: to be run by CRO Novotech in Australia, using Australia's R&D tax incentive (company cites over 40%) and the Clinical Trial Notification (CTN) scheme.
Monetisation: management has said it would prefer to partner MB-204 with a single pharmaceutical licensee rather than license indication by indication (Crux Investor interview).
Revenue model. Marvel has no product, service, subscription or licensing revenue. Every fiscal year from FY2020 to FY2025, and the trailing period to 30 Apr 2026, shows nil revenue (Weiss Ratings; TipRanks; Simply Wall St). The expected future model is licensing or partnering (upfront, milestones, royalties) or an outright sale of the asset. No such agreement has been disclosed.
Value chain position. Marvel sits at the earliest value-creating stage: IP generation plus preclinical and early clinical de-risking. It aims to exit before the expensive Phase II/III and commercial stages.
Target patients and end-markets. Rett syndrome (rare, mostly female, MECP2 mutations); Fragile X syndrome (the most common inherited cause of intellectual disability); autism spectrum disorder (socio-behavioural symptoms); depression and anxiety; Alzheimer's disease. Earlier corporate descriptions also list ADHD, NASH-associated liver fibrosis and immuno-oncology (A2A in cancer), but these are no longer the focus (moomoo profile; Yahoo Finance profile).
Independent characterisation. Marvel is a nano-cap "option on one molecule." The scientific rationale is credible. Istradefylline has human safety data, and A2A antagonism has peer-reviewed support in neuropsychiatric models. The company's choices are capital-efficient: an Australian Phase I, grant funding, and a contract CFO. However, the balance sheet is very weak. At 30 Apr 2026, current assets were about C$345K against well over C$1.8M of current liabilities. Each financing has been small: C$1.02M in May 2025 and C$1.60M in September 2026, the latter against a C$3.0M target. Value depends on (a) starting and completing Phase I, (b) using the rare-disease regulatory route (Orphan Drug Designation, possibly Rare Pediatric Disease designation) and (c) attracting a partner before dilution erodes shareholder value.
Strategy
Stated strategy (company themes, paraphrased):
-
Drug redevelopment: create patentable derivatives of approved drugs to lower development risk, cost and time.
-
Focus on neurodevelopmental rare diseases first: Rett syndrome and Fragile X, where orphan incentives and high unmet need support faster regulatory paths, then broaden to autism spectrum disorder and depression.
-
Capital-efficient clinical execution: Phase I in Australia for regulatory speed and tax-credit recovery.
-
Non-dilutive funding: NRC IRAP, Alberta Innovates AICE, and strategic co-funding from 5 Horizons.
-
Extend IP life: formulation patents (pediatric liquid) on top of composition-of-matter patents.
-
Partnering exit: prefer a single global partner for MB-204 (Crux Investor interview).
Medium-term targets / guidance. No financial targets have been issued. Operational guidance has been to start Phase I in Australia: first "Q2 2026" (5 Horizons release), and in an earlier interview "within 6–12 months" (Crux Investor). After Phase I, the company aims to go directly into Phase II/III studies in rare diseases. ESG and sustainability commitments have not been disclosed. There is no formal cost programme, but cost discipline is evident from the shrinking loss.
Products & Services
Marvel has no marketed products. The catalogue below lists its development assets.
MB-204 (lead asset)
| Attribute | Detail | Source |
|---|---|---|
| Description | A new fluorinated derivative of istradefylline (an approved anti-Parkinson's adenosine A2A antagonist) | Newsfile, 29 Sep 2026 |
| Mechanism | Selective adenosine A2A receptor antagonism; neuroactive | Novotech CRO release, 2026 |
| Claimed differentiation | Better pharmacokinetics than the parent compound; new composition-of-matter IP | StockTitan, Jun 2026 |
| Development stage | Preclinical, Phase I-ready. cGMP synthesis and 4-week GLP toxicology complete. Phase I (healthy volunteers: safety, tolerability, PK) planned in Australia with Novotech | INN; BioSpace (5 Horizons) |
| Phase I timing | Originally expected to start in Q2 2026 (5 Horizons release, Apr 2026). As of Sep 2026 the company was raising money for a Phase I deposit, so first dosing had not been announced | BioSpace; Newsfile, 29 Sep 2026 |
| Indications | Rett syndrome; Fragile X syndrome; autism spectrum disorder (socio-behavioural symptoms); depression; anxiety; Alzheimer's disease | Company releases |
| Key preclinical data | Rett: beat trofinetide across several behavioural endpoints, including after drug cessation. Fragile X: reversed behavioural and cognitive deficits in mice. Depression: rapid reversal of depressive behaviour in models (an interview cites about 90% reversal within an hour; company characterisation, not peer-reviewed) | StockAnalysis feed; Crux Investor |
| Formulations | Standard liquid formulation used in preclinical work. Two pediatric small-volume oral liquid formulations identified (Apr 2026) for oral syringe or feeding-tube dosing. New formulation patents filed | GlobeNewswire, 16 Apr 2026 |
| Target customer | Pediatric and adolescent patients with neurodevelopmental disorders; adults with depression; future pharma licensee | Company releases |
| Regulatory plans | FDA Orphan Drug Designation (Rett) planned; after Phase I, the company aims to move quickly into Phase II/III in rare-disease indications | BioSpace; moreblossom |
| Pricing | Not applicable (pre-commercial) | — |
Earlier-stage and historical pipeline
| Programme | Description | Status | Source |
|---|---|---|---|
| Other A2A antagonist derivatives | Further NCEs derived from off-patent drugs that inhibit the A2A receptor | Discovery; not prioritised | moomoo profile; roic.ai |
| Oncology (A2A in tumour immunology) | A2A inhibitors for cancer | Historical / deprioritised | roic.ai profile |
| NASH-associated liver fibrosis | Non-neurological use of MB-204 / A2A antagonism | Historical preclinical claim | Yahoo Finance profile |
| ADHD, Alzheimer's | Neurological indications in earlier corporate descriptions | Preclinical claims | moomoo; roic.ai |
| Non-hallucinogenic neuroplasticity programme | Listed in aggregator descriptions | Details not publicly disclosed | Yahoo Finance; Simply Wall St |
| Undisclosed targets | Company said it was exploring further undisclosed targets | — | moomoo profile |
Financial Narrative
Income statement
Sources: FY2021–FY2023 from TipRanks. FY2024 net income from TipRanks (rescaled) and roic.ai; FY2024 EPS from roic.ai. FY2025 from Weiss Ratings TTM at 31 Jul 2025. FY2025 weighted shares from roic.ai (rounded).
EPS discrepancies: roic.ai shows FY2021 at -0.17 against TipRanks -0.09, and FY2025 at -0.05 against Weiss -0.03. Weiss's TTM "average basic shares" of 174–228M is an aggregation error (it sums quarterly averages) and should be ignored.
FY2020 (Marvel Biotechnology Inc. predecessor): net loss C$955.66K; weighted shares 7.37M; EPS -0.13 (TipRanks).
Operating loss and EBITDA
Sources: TipRanks for FY2021–FY2024 EBITDA and FY2022–FY2024 operating loss; Weiss TTM for FY2025. FY2021 operating income appears in TipRanks as +806K, which is probably a classification artefact of RTO accounting, so it is excluded. FY2025 EBITDA is not reported by the aggregators.
Margins. Gross, operating, EBITDA and net margins are not meaningful because revenue is nil.
Revenue CAGR. Not meaningful (nil revenue).
Commentary. The loss has narrowed every year since the QT: from C$3.04M in FY2021 to about C$1.59M in FY2025, a fall of 48%. This reflects (a) one-off RTO and listing costs falling out after FY2021, (b) the end of expensive preclinical work (toxicology and cGMP synthesis) by FY2024–FY2025, and (c) tight cost control. FY2025 SG&A of about C$675K was more than 60% of operating expense, which signals very limited R&D spending in that year. The narrowing loss is a sign of constrained funding, not of operating leverage. The loss is expected to widen sharply once Phase I begins.
Recent quarters — FY2025 Q3 to FY2026 Q3
Source: Weiss Ratings quarterly statements (MBCOF).
The Q4 FY2025 loss of C$866K included about C$518K of non-cash items, consistent with year-end share-based compensation or debt and derivative adjustments. Q3 FY2026 reported positive net income of C$319K, alongside C$250K of negative non-cash items and a fall of about C$1.14M in current debt. This points to a gain on debt settlement, extinguishment or revaluation rather than operating income; the MD&A would be needed to confirm. The positive operating cash flow in Q3 FY2026 (C$120K) probably reflects grant receipts or working-capital timing.
Balance sheet
Source: roic.ai (rounded). FY2021 equity was about +C$2M (roic.ai), immediately after the QT.
FY2025 year-end detail (31 Jul 2025, Weiss): cash C$93.1K; total assets C$236.1K; accounts payable C$1.08M; accrued liabilities C$377.7K; current loans/debt C$1.67M. Derived net debt is about C$1.58M.
Goodwill and intangibles: nil on the balance sheet. Patents are expensed, not capitalised. Long-term debt: roic.ai shows about C$1M (FY2023) and C$2M (FY2024), reclassified to current by FY2025. The short-term versus long-term split for other years is not publicly disclosed.
Latest balance sheet (30 Apr 2026): cash C$317.8K; total assets C$344.8K; payables plus accruals about C$1.32M; current debt C$564.2K. Seeking Alpha reports total liabilities of about US$3.09M at 31 Oct 2025.
Cash flow
Source: Weiss Ratings TTM to 31 Jul 2025.
roic.ai free cash flow per share (C$, rounded), by roic year label: 2021 -0.08; 2022 -0.07; 2023 -0.03; 2024 -0.03; 2025 -0.02.
TTM to 30 Apr 2026: operating cash flow C$-569.1K; equity issued C$851.9K (Weiss).
Ratios
Interpretation. Marvel has been technically insolvent on a balance-sheet basis, with negative equity, since at least FY2023. It survives through repeated small placements, accrued payables that are effectively vendor financing, loans, and director fees paid in DSUs. The September 2026 placement (gross C$1.60M; about C$1.52M after cash finder fees of C$77K) is roughly two years of FY2025-level burn, but only before Phase I spending begins. The disclosed use of proceeds is a Phase I deposit, which implies the full trial cost is not yet funded.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (As Reported) Overview
| Segment (as reported) | Contents | Products / programmes | Segment operating result |
|---|---|---|---|
Single segment: drug development (Canada) | Marvel Biosciences Corp. (parent, listed) and Marvel Biotechnology Inc. (100% subsidiary, IP and R&D) | MB-204 and earlier-stage A2A antagonist derivatives | Equals consolidated operating loss |
Segment Revenue
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Drug development revenue (CAD K) | 0 | 0 | 0 |
Group Entities
| Entity | Role | Ownership |
|---|---|---|
Marvel Biosciences Corp. | TSXV-listed parent; formerly Alphanco Venture Corp. | Public |
Marvel Biotechnology Inc. | Operating and IP-holding subsidiary | 100% |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CAD K) | 0 | 0 | 0 | 0 | 0 |
Gross profit (CAD K) | 0 | 0 | 0 | 0 | 0 |
Pre-tax income (CAD K) | -3,040 | -2,550 | -2,290 | -1,650 | -1,590 |
Net income (CAD K) | -3,040 | -2,550 | -2,290 | -1,650 | -1,590 |
Basic EPS (CAD) | -0.09 | -0.08 | -0.06 | -0.04 | -0.03 |
Diluted EPS (CAD) | -0.09 | -0.08 | -0.06 | -0.04 | -0.03 |
Dividends per share (CAD) | 0 | 0 | 0 | 0 | 0 |
Weighted avg basic shares (M) | 32.59 | 32.76 | 39.66 | 39.96 | 47 |
Key Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Operating income (CAD K) | -2,540 | -2,320 | -1,220 | -1,070 |
SG&A (CAD K) | — | — | — | 675 |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
EBITDA (CAD K) | -1,250 | -2,510 | -2,250 | -1,540 |
Balance Sheet
| Metric | Q3FY25 (Apr-25) | Q4FY25 (Jul-25) | Q1FY26 (Oct-25) | Q2FY26 (Jan-26) | Q3FY26 (Apr-26) |
|---|---|---|---|---|---|
Total operating expenses (CAD K) | 176.1 | 355.7 | 182.2 | 189.3 | 248.5 |
SG&A (CAD K) | 175.8 | 173.3 | 140.8 | 185.4 | 195.8 |
Net income (CAD K) | -181.1 | -866.3 | -246.6 | -217.9 | 319.2 |
Cash from operations (CAD K) | -373.8 | -240.3 | -128.6 | -320.2 | 120.0 |
Equity issued (CAD K) | 925.0 | 93.8 | 683.1 | 75.0 | 0 |
Cash and ST investments (CAD K) | 281.5 | 93.1 | 452.1 | 202.1 | 317.8 |
Total assets (CAD K) | 362.2 | 236.1 | 487.4 | 235.6 | 344.8 |
Accounts payable (CAD K) | 1,010 | 1,080 | 1,150 | 1,060 | 1,080 |
Accrued liabilities (CAD K) | 234.4 | 377.7 | 297.6 | 315.0 | 239.0 |
Current debt / loans (CAD K) | 723.7 | 1,670 | 1,650 | 1,700 | 564.2 |
Liquidity & Coverage Ratios and Per-Share Data
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total equity (CAD Mn) | -2 | -3 | -4 |
Working capital (CAD Mn) | -1 | -3 | -4 |
Book value per share (CAD) | -0.05 | -0.08 | -0.09 |
Cash Flow
| Metric | FY2025 |
|---|---|
Operating cash flow (CAD K) | -824.9 |
Capex (CAD K) | 0 |
Free cash flow (CAD K) | -824.9 |
Equity issuance (CAD K) | 1,020 |
Financing cash flow (CAD K) | 658.3 |
Dividends paid (CAD K) | 0 |
Buybacks (CAD K) | 0 |
Net change in cash (CAD K) | -166.5 |
Financial Analysis
| Ratio | Value | Basis |
|---|---|---|
ROE | Not meaningful (negative equity) | — |
ROA | Roughly -670% (FY2025 net loss / year-end assets; derived, illustrative only) | Weiss data |
Current ratio | About 0.08 (31 Jul 2025); about 0.18 (30 Apr 2026) | Derived from Weiss current assets / identified current liabilities |
Debt / equity | Not meaningful (negative equity) | — |
Net debt / EBITDA | Not meaningful (negative EBITDA) | — |
Interest coverage | Not meaningful (negative EBIT) | — |
Asset turnover | 0 (nil revenue) | — |
Geographic Revenue
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Canada revenue (CAD K) | 0 | 0 | 0 |
Australia revenue (CAD K) | 0 | 0 | 0 |
United States revenue (CAD K) | 0 | 0 | 0 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Recent share price (TSXV) | About C$0.16 | Investing.com; roic.ai |
52-week range | C$0.13–0.32 | Investing.com |
Recent placement price | C$0.15 (Sep 2026) | Newsfile |
Market cap | About C$10.1–10.4M (pre-placement); about C$11.8M (post-placement, derived) | roic.ai; Investing.com |
Enterprise value | About US$7.05M (Jan 2026, Yahoo, MBCOF) | Yahoo Finance |
OTC (MBCOF) price | About US$0.10–0.11 | Yahoo; Weiss |
P/E | n/m (losses) | — |
EV/EBITDA | n/m | — |
EV/Sales | n/m | — |
P/B | n/m (negative book value) | — |
Analyst consensus | None; no sell-side coverage and no EPS estimates | Wealth Awesome, Jun 2026 |
Dividend history / policy | Never paid; none expected | Aggregators |
Credit ratings (Moody's / S&P / Fitch) | Not rated | — |
Debt maturity profile | Loans and debt classed as current (C$564K at 30 Apr 2026); detailed schedule not publicly disclosed | Weiss |
Share Count (M)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Weighted avg basic shares (M) | 32.59 | 32.76 | 39.66 | 39.96 | 47 |
Analyst Conclusions
Management guidance. The company plans to start a healthy-volunteer Phase I of MB-204 in Australia with Novotech, funded by the September 2026 placement (deposit), Alberta Innovates AICE, 5 Horizons co-funding and the Australian R&D tax incentive. It intends to seek FDA Orphan Drug Designation in Rett and then move into Phase II/III in rare diseases. No financial guidance has been given and there is no consensus forecast.
Bull case:
-
Mechanism plus IP. A derivative of an approved, human-validated A2A antagonist with composition-of-matter protection in the US, China, Japan and Australia offers an unusually de-risked starting point for a nano-cap.
-
Rare-disease economics. Daybue's revenue (about US$348M in FY2024) proves Rett patients and payers will fund therapy. Positive Phase I data plus Orphan Drug Designation could re-rate a company valued at about C$12M.
-
Cheap trial and validation. Australian tax credits and three outside funders lower the net Phase I cost and lend credibility.
Bear case:
-
Solvency. Negative equity of about -C$4M, payables of about C$1.1M and a raise only half filled show investor demand is constrained. Funding the full Phase I is likely to need further placements below or near C$0.15.
-
Translational risk. All efficacy evidence comes from company-reported mouse studies. ASD and Fragile X have a long record of trial failures.
-
Competitive and timeline risk. Phase I has already slipped beyond Q2 2026. Gene therapies and late-stage Fragile X assets may set the standard of care before MB-204 reaches efficacy trials.
Analyst verdict. Alphanco Venture Corp. is no longer a company in its own right. It was the TSXV capital pool shell that became Marvel Biosciences Corp. in mid-2021, and anyone holding the "AVC.P / Australia" record should update it to TSXV: MRVL / OTCQB: MBCOF, Calgary, Canada. Marvel is a tightly run but financially fragile single-asset biotech. Its scientific idea is coherent: take the only approved adenosine A2A antagonist, fluorinate it for better pharmacokinetics and new patents, and aim it at socio-behavioural symptoms in rare neurodevelopmental disorders, where approved options are scarce and orphan incentives are strong. Execution has been solid on a small budget. In 2026 alone the company completed cGMP/GLP readiness, built a four-jurisdiction composition-of-matter estate, selected a CRO, identified pediatric formulations and secured three non-dilutive or strategic funders. Annual losses fell by nearly half from FY2021 to FY2025.
The financial position, however, overrides the science in the near term. Equity is negative, working capital is deeply negative, and suppliers are carrying more than C$1M of payables. The latest placement raised only C$1.6M of a C$3.0M target, after two deadline extensions, and was explicitly sized for a Phase I deposit. Investors should therefore expect further dilution before any human data arrive. The share count has already nearly doubled since FY2024. The Phase I start has slipped past guidance, and every efficacy claim so far comes from mouse studies reported by the company.
On balance, MRVL is a speculative, binary, venture-style exposure. The decisive monitorables are the FY2026 going-concern disclosure, confirmation that the first subject has been dosed in Australia, and any Orphan Drug Designation progress. A partnership with an A2A-experienced or Rett-focused company (Kyowa Kirin, Acadia or similar) would transform the risk profile. Without one, the base case is incremental, dilutive progress, with value depending on Phase I safety and PK data expected in 2027 at the earliest.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation (latest available) | Source |
|---|---|---|---|---|---|
J. Roderick (Rod) Matheson | Executive Chairman and CEO | CEO since Jul 2021 (about 5.2 yrs) | Was CEO of Marvel Biotechnology before the QT; owns about 11.2% of shares | C$150K total, all salary (Simply Wall St). Yahoo shows C$109.6K. Sources conflict | Simply Wall St; Yahoo Finance |
Dr. Mark Williams, PhD, MBA | President, Chief Science Officer and Director | Since at least 2021 | Scientific lead; born 1972 | C$109.6K (Yahoo) | Yahoo Finance; Newsfile |
Harpreet (Harry) Nijjar, CPA, CMA | Chief Financial Officer | Since 1 Feb 2022 | Managing Director at Malaspina Consultants (contract CFO services, joined 2011); born 1988 | C$84K (Simply Wall St) vs C$60.3K (Yahoo). Sources conflict | Newsfile, 1 Feb 2022; Yahoo; Simply Wall St |
Jacqueline Groot | Corporate Secretary | — | — | — | Yahoo; moomoo |
Preston Maddin | Former CFO | Until 31 Jan 2022 | — | — | Newsfile, 1 Feb 2022 |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Independent | Background | Source |
|---|---|---|---|---|
J. Roderick Matheson | Chair | No (executive) | CEO | Newsfile AGM release |
Dr. Mark Williams | Director | No (executive) | President and CSO | moomoo |
Neil A. Johnson | Lead Independent Director | Yes | — | moomoo |
S. Randall Smallbone | Director | Yes | Former CFO of three public companies (Migao, KCP Income Fund, Decoma International/Magna); chairs Burlington Economic Development Corp. and Joseph Brant Hospital boards | Newsfile AGM release |
Babak Pedram | Director (since 23 Nov 2022) | Yes | More than 15 years in investment banking and capital-markets advisory; founder and president of Virtus Advisory Group (the company's former IR firm); BSc and MSc, Queen's University | Newsfile, 24 Nov 2022 |
Jeremy Fehr | Director (elected 2022) | — | — | Newsfile AGM release; moomoo |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
J. Roderick Matheson (CEO) | About 11.2% | Simply Wall St |
Institutional holders (top 10) | Not publicly disclosed; institutional ownership is believed to be negligible for a TSXV nano-cap | — |
5 Horizons Ventures | Strategic funding partner (15% of Phase I CRO costs); any equity stake not disclosed | BioSpace, Apr 2026 |
Competitive Landscape
Competitors by Segment
| Area | Competitor | Asset / approach | Stage | Approx. scale | Relative positioning against Marvel |
|---|---|---|---|---|---|
Rett syndrome | Acadia Pharmaceuticals (NASDAQ: ACAD) | Trofinetide (Daybue), the only FDA-approved Rett therapy | Marketed | FY2024 revenue about US$958M (Daybue about US$348M) | Incumbent; MB-204 claims better preclinical efficacy |
Rett syndrome | Neurogene (NASDAQ: NGNE) | NGN-401 gene therapy | Clinical | Pre-revenue | Disease-modifying approach |
Rett syndrome | Taysha Gene Therapies (NASDAQ: TSHA) | TSHA-102 gene therapy | Clinical | Pre-revenue | Disease-modifying approach |
Rett / CNS | Anavex Life Sciences (NASDAQ: AVXL) | Blarcamesine (sigma-1) | Clinical | Pre-revenue | Small-molecule competitor |
Fragile X | Harmony Biosciences (NASDAQ: HRMY; acquired Zynerba) | Zygel (cannabidiol gel) | Late clinical | FY2024 revenue about US$715M | Late-stage rival |
Fragile X | Shionogi / Tetra Therapeutics | Zatolmilast (PDE4D inhibitor) | Late clinical | Shionogi is a large pharma | Late-stage rival |
A2A antagonism (Parkinson's) | Kyowa Kirin (TSE: 4151) | Istradefylline (Nourianz/Nouriast), the parent molecule | Marketed | Group revenue about ¥0.5 trillion | Validates the mechanism; possible partner or competitor |
A2A antagonism (oncology) | Arcus Biosciences (NYSE: RCUS); Corvus (NASDAQ: CRVS) | Etrumadenant; ciforadenant | Clinical | Collaboration revenue (Arcus) | Same target, different therapeutic area |
Autism (socio-behavioural) | Various: oxytocin and vasopressin-pathway programmes, bumetanide programmes (several failed) | Various | Clinical / failed | — | Field with many failures; high bar |
Depression | J&J (Spravato), Sage/Biogen (zuranolone) and others | Various | Marketed | Very large | Crowded; MB-204's depression positioning is secondary |
Peer Comparison FY2025
| Metric | Marvel Biosciences | Acadia | Neurogene | Taysha |
|---|---|---|---|---|
Latest FY revenue | C$0 (FY2025) | About US$958M (FY2024) | Pre-revenue | Pre-revenue |
Revenue growth | — | Positive (Daybue launch) | — | — |
Operating margin | n/m | Positive (FY2024) | n/m | n/m |
R&D intensity | About C$0.4M absolute (FY2025 proxy) | Significant (hundreds of US$M) | Tens of US$M | Tens of US$M |
Stage of lead Rett asset | Preclinical (Phase I pending) | Approved | Phase 1/2 | Phase 1/2 |
Recent Developments
The Phase I timing has, however, slipped beyond the Q2 2026 guidance.



